Ibio Inc (IBIO)
$2.03
0.18 (9.73%)
IBIO Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
7.07M
PE Ratio
-0.41
EPS
-4.95
Volume (Avg. Vol.)
618,383
Day's Range
$1.86 - $2.18
52-Week Range
$0.20 - $4.49
Dividend & Yield
N/A (N/A)
IBIO Stock Predictions, Articles, and Ibio Inc News
A Lack of Progress Keeps IBIO Shares As a Sell
Investors bought the Covid-19 hype in IBIO stock. With little progress made, however, reality is setting in, which means the fade should continue.
Firming Financials Point to an Underappreciation of iBio Stock
The IBIO stock price is down, but that doesn't mean the company's in trouble. In fact, the data shows that iBio's fiscal health is improving.
Why iBio Remains Worth a Look In a Post-Pandemic Landscape
While its shot at pioneering a novel coronavirus vaccine has passed, iBio and its IBIO stock could benefit from other medical breakthroughs.
Biotech Innovator IBIO Is Down, but Not Out for the Long Term
Biotech innovator IBIO stock has been tossed around based on iBio’s COVID-19 vaccine progress, but its FastPharma tech is the long-term play.
iBio News: Why IBIO Stock Is Soaring 16% Today
Ibio (IBIO) is seeing shares of IBIO stock soar higher on Wednesday following news of a contract for the biotech company.
The Case for iBio Stock Is Real, but Leaves a Key Question Unanswered
iBio has a long-standing relationship with the United States defense industry. But that hasn't enough to give IBIO stock a leg up in the Covid-19 race.
It’s Time for iBio Speculators to Consider Something Else
One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibilities.
iBio Looks Well-Positioned to Succeed
iBio reports impressive Q1 results as biotech companies see a strong rally this year. Here’s the latest on IBIO stock.
Why iBio Presents a Dilemma to Shareholders
iBio’s first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.
Stay Away From iBio, Which Constantly Issues Shares to Survive
The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.
Up 600% Year-to-Date, Sell iBio Stock While It’s Still Flying High
The latest iBio news isn't good. It's taken too long for IBIO to develop a coronavirus vaccine and now the opportunity has disappeared.
Two Covid-19 Vaccine Candidates Hold Promise for iBio
iBio has a huge vertical farming facility and a couple of high-potential vaccine candidates, which should offer hope to IBIO stock holders.
iBio Remains a Biotech Sideline Play as Covid Rages
Investor interest a unique production system isn’t enough to make buying IBIO stock a worthwhile move at this time.
First to COVID-19 Vaccine or Not, iBio Is a Smart Investment
IBIO stock has been hit hard by its apparent failure to produce the first COVID-19 vaccine, but that’s a simplistic view of iBio’s prospects.
IBIO Stock Remains a Speculative Biopharma Play
Yes, I will continue to root for Ibio in its fight to make a huge leap with its Covid-19 efforts. But where my investment dollar is concerned, it'll be from the sidelines.
The Low-Hanging Fruit for Covid-19 Vaccines Is Gone for iBio
With the viable candidate pool for novel coronavirus vaccines shrinking, this angle is probably closed to IBIO stock. However, speculators still have a shot with the therapeutic approach.
IBIO Remains a Purely Speculative Bet
IBIO stock is a purely speculative bet compared to better options when it comes to investing in Covid-19 vaccine development.
Why iBio Is a Buy for Investors Thinking Past the Vaccine Race
An investment in IBIO stock is a bet on the company’s unique FastPharming system to create medications and therapies of all sorts.
IBio Stock Is Not Worth a Gamble at This Stage
IBIO stock is in a rough spot with minimal progress in its Covid-19 vaccine and its FastPharming technology.
